Galapagos
- Country
- 🇧🇪Belgium
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1.1K
- Market Cap
- $1.9B
- Website
- http://www.glpg.com
- Introduction
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in M...
Oral Bioavailability of Two Solid Formulations of GLPG0259.
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 12
- Registration Number
- NCT01322451
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 20
- Registration Number
- NCT01313598
- Locations
- 🇳🇱
Nationaal Kanker Instituut (NKI), Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum, Utrecht, Netherlands
Oral Bioavailability of GLPG0555 in Different Solid Formulations
- Conditions
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 12
- Registration Number
- NCT01278095
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
First-in-Human Single Ascending and Multiple Dose of GLPG0778
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2011-10-18
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 40
- Registration Number
- NCT01278108
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 30
- Registration Number
- NCT01211249
- Locations
- 🇵🇱
Synexus SCM Sp. z o.o., Wrocław, Poland
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇳🇱UMC Leiden, Leiden, Netherlands
Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 24
- Registration Number
- NCT01208753
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
First-in-Human Single Ascending and Multiple Dose of GLPG0634
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 48
- Registration Number
- NCT01179581
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
First-in-Human Single Ascending Dose of GLPG0492
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 28
- Registration Number
- NCT01130818
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 15
- Registration Number
- NCT01039103
- Locations
- 🇵🇱
Diagnomed-Clinical Research Sp. z o.o., Katowice, Poland
🇩🇪St. Josef Hospital der Ruhr, Bochum, Germany
🇩🇪Klinikum Rechts der Isar der technischen Universitaet Muenchen, Neurologische Klinik und Poliklinik, Muenchen, Germany
First-in-Human Single Ascending and Multiple Dose of GLPG0555
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2010-08-12
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 35
- Registration Number
- NCT01023321
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium